Formycon
Munich, Germany· Est. 2009
As a globally operating, independent biosimilar developer, Formycon actively contributes to improving patients' access to high-quality, safe and affordable biologic medicines.
Private Company
Total funding raised: $145M
About
As a globally operating, independent biosimilar developer, Formycon actively contributes to improving patients' access to high-quality, safe and affordable biologic medicines.
Biosimilars
Funding History
4Total raised:$145M
Debt$30MJun 15, 2019
IPO$50MSep 30, 2015
Series B$40MJun 15, 2013
Series A$25MJun 15, 2010